Low-molecular-weight heparins: pharmacologic profile and product differentiation
- 1 September 1998
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 82 (5) , 3L-10L
- https://doi.org/10.1016/s0002-9149(98)00105-2
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary EmbolismNew England Journal of Medicine, 1997
- Low-Molecular-Weight Heparin in the Treatment of Patients with Venous ThromboembolismNew England Journal of Medicine, 1997
- Heparin in Acute Coronary Disease — Requiem for a Heavyweight?New England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997
- Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1996
- The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparinBlood Coagulation & Fibrinolysis, 1995
- Tissue factor pathway inhibitor and the current concept of blood coagulationBlood Coagulation & Fibrinolysis, 1995
- Rat jugular vein hemostasis - a new model for testing antithrombotic agentsThrombosis Research, 1989
- A Primate Model (Macaca Mulatta) to Study the Pharmacokinetics of Heparin and Its FractionsSeminars in Thrombosis and Hemostasis, 1985
- A Modified Stasis Thrombosis Model to Study the Antithrombotic Actions of Heparin and Its FractionsSeminars in Thrombosis and Hemostasis, 1985